After replenishing its stock, Double Bond Pharmaceuticals subsidiary Drugsson AB has now received an order from Apotek365.

The products will soon be sold at online pharmacies again.

As previously announced, Zoono's products protect and prevent the spread of the COVID-19 virus in addition to hundreds of other pathogens (https://mb.cision.com/Main/12720/3059273/1210993.pdf, https://zoono.com/pages / corona virus)

'We are very pleased that we can supply the market with unique, safe and effective products in a short time, especially now that the situation with covid-19 is becoming more difficult,' - says Igor Lokot, CEO of Drugsson and DBP.

More about Zoono: http://www.zoono.com

More about Drugsson AB: www.drugsson.com

Full company name: Double Bond Pharmaceutical International AB (publ)

Organization number: 556991-6082

Share name: DBP B

Share ISIN code: SE0007185525

Contact:

Igor Lokot

Email: info@doublebp.com

Web: http://www.doublebp.com

Information about Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with operations that focus primarily on the treatment of cancer diseases through an in-house developed drug delivery technology. In June 2015, the company was granted Orphan Drug Designation status by the European Medicines Agency (EMA) for its first product, SA-033, for the treatment of hepatoblastoma. In October 2015, Double Bond Pharmaceutical acquired the rights to Temodex - a drug registered in Belarus for the treatment of brain tumors. In July 2016, the company was granted Orphan Drug Designation status by EMA for Temodex.

(C) 2020 Electronic News Publishing, source ENP Newswire